Two migraine patients were studied by in vivo SPECT using the dopamine D2–receptor specific radioligand 123I-3–iodo-6–methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal. Results were compared with 15 healthy controls. Striatum/cerebellum and striatum/occipital cortex ratios of count rate density were calculated as a semiquantitative measurement for striatal dopamine D2–receptor binding potential. No differences were found in striatal uptake of 123I-IBZM between healthy controls and the patients when on or off ergotamine. Preliminary evidence suggests that ergotamine may not occupy striatal dopamine D2–receptors to a large extent and thus may not cross the blood brain barrier in large quantities.
BuzziMGCarterWBShinizuTHeathHIIIMoskowitzMADihydroergotamine and sumatriptan attenuate the increase in plasma calcitonin gene-related peptide levels within a rat superior sagittal sinus during electrical trigeminal ganglion stimulation.Neuropharmacology1991;30:1193–200
2.
SaxenaPRKoedamNAHeiligersJHofRPErgotamine-induced constriction of cranial arteriovenous anastomoses in dogs pretreated with phentolamine and pizotifen.Cephalalgia1983;3:71–81
3.
GoadsbyPJGundlachALLocalization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine.Ann Neurol1991;29:91–4
4.
Den BoerMOHeiligersJPCSaxenaPRCarotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5--HT1--like receptors.Br J Pharmacol1991;104:183–9
5.
PerrinVLClinical pharmacokinetics of ergotamine in migraine and cluster headache.Clin Pharmacokinet1985;10:334–52
6.
BadiaAMoronACuffiLVilaEEffects of ergotamine on cardiovascular dopamine receptors in the pithed rat.Gen Pharmacol1988;19:475–81
7.
CarlsonMDKishPEUedaTGlutamate uptake into synaptic vesicles: competitive inhibition by bromocriptine.J Neurochem1989;53:1889–94
8.
LofströmAAgnatiLFFuxèKHokfeltTEvidence for an inhibitory dopaminergic and stimulatory noradrenergic hypothalamic influence on PMS-induced ovulation in the immature rat. II. A pharmacological analysis.Neuroendocrinology1977;24:289–316
9.
SpanoPFTrabucchiMInteraction of ergot alkaloids with dopaminergic receptors in the rat striatum and nucleus accumbens.Gerontology1978;24(suppl 1):106–14
10.
TrabucchiMHofmannMMontefuscoOSpanoPFErgot alkaloids and cyclic nucleotides in the CNS.Pharmacology1978;16(suppl 1):150–5
11.
HorowskiRGrafKJNeuroendocrine effects of neuropsychotropic drugs and their possible influence on toxic reactions in animals and man-the role of the dopamine-prolactin system.Arch Toxicol Suppl1979;93–104
12.
HyttelJFurther evidence that 3H-cis(Z)flupenthixol binds to the adenylate cyclase-associated dopamine receptor (D-I) in rat curpus striatum.Psychopharmacology1980;67:107–9
13.
LeysenJEGommerenWIn vitro receptor binding profile of drugs used in migraine. In:AmeryWKVan NuetenJMWauquierA eds.The pharmacological basis of migraine therapy.London:Pitman,1984:255–66
14.
Del BiancoPLFranchiGAnselmiBSicuteriFMonoamine sensitivity of smooth muscle in vivo in nociception disorders.Adv Neurol1982;33:391–8
15.
CostaDCVerhoeffNPLGCullumIDEiiPJSyedGMSBarrettJPalazidouETooneBVan RoyenEABobeldijkMIn vivo characterisation of 3--iodo-6--methoxybenzamide 123I in humans.Eur J Nucl Med1990;16:813–16
16.
VerhoeffNPLGCostaDCEllPJTooneBPalasidouECullumIDBobeldijkMMillerRSyedGMSBarrettJJSoricelliAVan RoyenEADopamine D2--receptor imaging with dynamic I-123 IBZM SPECT in patients with schizophrenia or HIV encephalopathy.Nucl Med1991(suppl 72):207–12
17.
SchaltenbrandGWahrenWAtlas for stereotaxy of the human brain.Stuttgart:Georg Thieme,1977
18.
MatsuiTHiranoAAn atlas of the human brain for computerised tomography.Stuttgart:Gustav Fischer Verlag,1978
19.
LidowMSGoldman-RakicPSRakicPInnisRBDopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride.Proc Natl Acad Sci USA1989;86:6412–16
20.
PilowskyLSCostaDCEllPJMurrayRMVerhoeffNPLGKerwinRWClozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.Lancet1992;340:199–202
21.
BaldessariniRJFrankenburgFRClozapine. A novel antipsychotic agent.N Engl J Med1991;324:746–54
22.
LeendersKLWolfsonLGibbsJMWiseRJSCausonRJonesTLeggNJThe effects of I-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease.Brain1985;108:171–91
23.
De KeyserJEbingerGDe BackerJPConventsAVanderheydenPVauquelinGSubtypes of adrenergic and dopaminergic receptors in bovine cerebral blood vessels.Neurosci Left1958;85:272
